LABELS · c48edbf8-425f-4e11-8892-467e868d9fba

ZOLADEX

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-03-24
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.5 )]. The automatic safety feature of the syringe aids in the prevention of needlestick injury.

Full extracted label fields

application numbers

NDA019726

boxed warning exact

brand names

ZOLADEX

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3

generic names

GOSERELIN

c48edbf8-425f-4e11-8892-467e868d9fba

indications and usage exact

1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.5 )]. The automatic safety feature of the syringe aids in the prevention of needlestick injury.

indications and usage tables exact

is original packager

true

manufacturer names

TerSera Therapeutics LLC

matched search terms

cancer
carcinoma

package ndcs

70720-950-36

product ndcs

70720-950

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions ( 5.7 ) 9/2025

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

105641
310592

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 720
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment wit
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 0

current approval status

not_reconciled

duplicate text group

dup-89063086b74fc7ccb106

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-92a8700884b9ee327a81

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 92
end exclusive: true
exact text: is a Gonadotropin Releasing Hormone (GnRH) agonist indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 32

qualifier mentions

context exact
d carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endom
kind
stage_or_setting
polarity
not_inferred
span
end
267
end exclusive
true
exact text
advanced carcinoma of the prostate ( 1
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
229
context exact
uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
500
end exclusive
true
exact text
advanced breast cancer in pre- and perimeno
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
457
context exact
otropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prost
kind
regimen
polarity
not_inferred
span
end
200
end exclusive
true
exact text
in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
102

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 520
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 )
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 906
end exclusive: true
exact text: endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 321

current approval status

not_reconciled

duplicate text group

dup-b54dc045a39f319c13e9

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-4988515048c77a25c935

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 576
end exclusive: true
exact text: is indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 564

qualifier mentions

context exact
Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate.
kind
regimen
polarity
not_inferred
span
end
705
end exclusive
true
exact text
in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
585

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 706
end exclusive: true
exact text: 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 521

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1111
end exclusive: true
exact text: women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 507

current approval status

not_reconciled

duplicate text group

dup-b4b6a88c93d0dd5c3415

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-0da6dd2cfc9e40d72f0f

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 911
end exclusive: true
exact text: Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )].
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 707

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1293
end exclusive: true
exact text: ment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the m
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 712

current approval status

not_reconciled

duplicate text group

dup-0b8109182e4ee56caf59

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-f0732bfe8d5c129a470a

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 956
end exclusive: true
exact text: is indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 944

qualifier mentions

context exact
rcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )
kind
stage_or_setting
polarity
not_inferred
span
end
1031
end exclusive
true
exact text
advanced carcinoma of the prostate [see Dos
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
988

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1093
end exclusive: true
exact text: 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )].
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 912

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1459
end exclusive: true
exact text: tudies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 894

current approval status

not_reconciled

duplicate text group

dup-bff14a857ef9290077dd

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-f2e4ebc17e6e8dc03a41

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 1132
end exclusive: true
exact text: is indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1120

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1259
end exclusive: true
exact text: 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1094

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1663
end exclusive: true
exact text: ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clin
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1060

current approval status

not_reconciled

duplicate text group

dup-20035cbc4fae03c1610c

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-9bec2217a415d5860a6a

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

Source null

qualifier mentions

context exact
r the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administrati
kind
age
polarity
not_inferred
span
end
1361
end exclusive
true
exact text
18 years of age
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
1346

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1463
end exclusive: true
exact text: Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )].
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1260

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1886
end exclusive: true
exact text: rience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1264

current approval status

not_reconciled

duplicate text group

dup-198674d8a01d1cdf68ae

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-01bccafb253072426199

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 1509
end exclusive: true
exact text: is indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1497

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1686
end exclusive: true
exact text: 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )].
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1464

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2030
end exclusive: true
exact text: g ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinic
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1487

current approval status

not_reconciled

duplicate text group

dup-0f0d87ee2b7b3cb21074

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-2c61d4f528406711b360

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

end: 1734
end exclusive: true
exact text: is indicated
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1722

qualifier mentions

context exact
1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast canc
kind
stage_or_setting
polarity
not_inferred
span
end
1734
end exclusive
true
exact text
Advanced Breast Cancer ZOLADEX is indicated
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
1691
context exact
ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.
kind
stage_or_setting
polarity
not_inferred
span
end
1817
end exclusive
true
exact text
advanced breast cancer in pre- and perimeno
label id
c48edbf8-425f-4e11-8892-467e868d9fba
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start
1774

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1830
end exclusive: true
exact text: 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1687

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · unclassified context

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2141
end exclusive: true
exact text: Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.5 )]. The automatic safety feature of the syringe aids in the prevention of needlestick injury.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1631

current approval status

not_reconciled

duplicate text group

dup-e5197c742d303bb84990

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-e79756a6acdcbe6f06a0

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2051
end exclusive: true
exact text: The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.5 )].
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1831

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA019726

brand names

ZOLADEX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2141
end exclusive: true
exact text: esterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.5 )]. The automatic safety feature of the syringe aids in the prevention of needlestick injury.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 1852

current approval status

not_reconciled

duplicate text group

dup-4f720cbd3389e054c890

extraction review status

automated_candidate_pending_source_review

generic names

GOSERELIN

ind-span-3a0ea744c09594bc2642

label id

c48edbf8-425f-4e11-8892-467e868d9fba

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2141
end exclusive: true
exact text: The automatic safety feature of the syringe aids in the prevention of needlestick injury.
label id: c48edbf8-425f-4e11-8892-467e868d9fba
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f3006870e5ef0e2cb7ab08b9f447ab89489aaf269ca308b05d54a319621aab68
start: 2052

source url

https://api.fda.gov/drug/label.json?search=id%3A%22c48edbf8-425f-4e11-8892-467e868d9fba%22

spl effective date

2026-03-24

spl set id

294b168b-6e5f-4db9-bf70-d599271458b3

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice